First-in-Human Study of a Pharmacological Duodenal Exclusion Therapy Mimics a Roux-en-Y Gastric Bypass Biomarker Signature

Duodenal Targeting by Oral Pharmacologic Duodenal Exclusion Therapy for Treatment of Type 2 Diabetes (T2D)

Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat

GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat

GLY-200: A novel polymer therapeutic for metabolic diseases

Forging Success in Type 2 Diabetes: Treatment & Reversal of T2D & Interrogating Cross-Talk in Metabolic Syndrome

A First-in-Human Study of GLY-200, an Oral, Gut-Restricted, Pharmacologic Duodenal Exclusion Therapy

Validation of duodenal targeting by oral pharmacologic duodenal exclusion therapy for treatment of type 2 diabetes

Chronic Oral Polymeric Duodenal Exclusion Therapy Has Profound Metabolic Benefits in a T2D Rat Model and Affects Duodenal Morphological Enteroplasticity Similar to RYGB surgery: Implications for T2D Therapy

Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy

Robust metabolic benefits of a novel orally administered polymeric duodenal exclusion therapy in animal models of type 2 diabetes: an alternative treatment for type 2 diabetes

Profound Metabolic Benefits Observed in an Eight-Week GK Rat Study of a Novel Orally Administered Polymeric Duodenal Exclusion Therapy: Implications for Type 2 Diabetes (T2D) Therapy